PCM
ABUS icon

Prelude Capital Management’s Arbutus Biopharma ABUS Stock Holding History

Prelude Capital Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-45,300
Closed -$161K – 1505
2020
Q4 		$161K Buy
45,300
+300
+0.7% +$1.05K ﹤0.01% 1144
2020
Q3 		$141K Buy
+45,000
New +$137K 0.01% 792

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Prelude Capital Management's ABUS Position: Q2 2026 in Review

Prelude Capital Management sold out of Arbutus Biopharma (ABUS) in Q2 2026, closing a stake of 25,318 shares — an estimated $114K sold.

Prelude Capital Management first reported a position in ABUS in Q4 2014 and held it in 17 quarters. The position peaked at $186K in Q2 2022. 176 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • Prelude Capital Management reported no remaining Arbutus Biopharma position as of Q2 2026 after selling out during the quarter.
  • Prelude Capital Management sold 25,318 Arbutus Biopharma shares in Q2 2026, an estimated $114K.
  • Prelude Capital Management first reported a position in Arbutus Biopharma in Q4 2014 and held it in 17 quarters.
  • Prelude Capital Management's Arbutus Biopharma position peaked at $186K in Q2 2022.
  • 176 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.